{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:44:27Z","timestamp":1794411867500,"version":"4.9.0"},"reference-count":188,"publisher":"Elsevier","isbn-type":[{"value":"9780123964564","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.1016\/b978-0-12-396456-4.00007-9","type":"book-chapter","created":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T02:39:34Z","timestamp":1329187174000},"page":"107-142","source":"Crossref","is-referenced-by-count":10,"title":["The Role of Protein Phosphorylation in Therapy Resistance and Disease Progression in Chronic Myelogenous Leukemia"],"prefix":"10.1016","author":[{"given":"Wen Chun","family":"Juan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Tiong","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0005","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1128\/MCB.9.3.1263","article-title":"The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc","volume":"9","author":"Lugo","year":"1989","journal-title":"Mol Cell Biol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0010","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0015","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0020","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0025","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1002\/cncr.25123","article-title":"Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily","volume":"116","author":"Saglio","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0030","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0035","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0040","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0045","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/cncr.20285","article-title":"Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia","volume":"100","author":"Quintas-Cardama","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0050","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-06-3126","article-title":"Cancer stem cells\u2014perspectives on current status and future directions: AACR Workshop on cancer stem cells","volume":"66","author":"Clarke","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0055","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/stemcells.2005-0116","article-title":"A side order of stem cells: the SP phenotype","volume":"24","author":"Challen","year":"2006","journal-title":"Stem Cells"},{"issue":"Suppl. 4","key":"10.1016\/B978-0-12-396456-4.00007-9_bb0065","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.3816\/CLM.2009.s.037","article-title":"The chronic myeloid leukemia stem cell","volume":"9","author":"Nicholson","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr-Abl tyrosine kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0075","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1073\/pnas.95.13.7457","article-title":"Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase","volume":"95","author":"Taagepera","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/84683","article-title":"Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase","volume":"7","author":"Vigneri","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0085","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0090","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/0092-8674(91)90011-M","article-title":"Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene","volume":"65","author":"Tybulewicz","year":"1991","journal-title":"Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0095","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1126\/science.3263702","article-title":"Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors","volume":"242","author":"Yaish","year":"1988","journal-title":"Science"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0100","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0105","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nn1071","article-title":"Postsynaptic requirement for Abl kinases in assembly of the neuromuscular junction","volume":"6","author":"Finn","year":"2003","journal-title":"Nat Neurosci"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0110","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","article-title":"Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis","volume":"14","author":"Shah","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","article-title":"BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein","volume":"75","author":"Pendergast","year":"1993","journal-title":"Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0120","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V96.2.664","article-title":"The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr\/Abl tyrosine kinase","volume":"96","author":"Million","year":"2000","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0125","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1182\/blood.V98.6.1773","article-title":"Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes","volume":"98","author":"Kardinal","year":"2001","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0130","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ccr.2007.10.015","article-title":"Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease","volume":"12","author":"Thomas","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood-2009-10-247437","article-title":"Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo","volume":"116","author":"Sengupta","year":"2010","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0140","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2002-05-1598","article-title":"JunB gene expression is inactivated by methylation in chronic myeloid leukemia","volume":"101","author":"Yang","year":"2003","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0092-8674(01)00188-X","article-title":"Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage","volume":"104","author":"Passegue","year":"2001","journal-title":"Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0150","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cell.2004.10.010","article-title":"JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells","volume":"119","author":"Passegue","year":"2004","journal-title":"Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0155","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.leu.2402945","article-title":"Signal transduction mediated by the Ras\/Raf\/MEK\/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0160","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2005-09-3732","article-title":"A MAPK\/HNRPK pathway controls BCR\/ABL oncogenic potential by regulating MYC mRNA translation","volume":"107","author":"Notari","year":"2006","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0165","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1093\/emboj\/19.9.2056","article-title":"Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression","volume":"19","author":"Bakiri","year":"2000","journal-title":"EMBO J"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0170","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1073\/pnas.050586197","article-title":"Identification of CDK4 as a target of c-MYC","volume":"97","author":"Hermeking","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0175","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/1074-7613(95)90028-4","article-title":"Coordinate and cooperative roles for NF-AT and AP-1 in the regulation of the murine IL-4 gene","volume":"2","author":"Rooney","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0180","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.4049\/jimmunol.159.10.4720","article-title":"Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients","volume":"159","author":"Chai","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0185","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood.V95.6.2118","article-title":"STAT5 activation contributes to growth and viability in Bcr\/Abl-transformed cells","volume":"95","author":"Sillaber","year":"2000","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0190","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/blood-2005-09-3596","article-title":"Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation","volume":"107","author":"Hoelbl","year":"2006","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0195","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0200","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1093\/emboj\/cdf562","article-title":"The Src family kinase Hck couples BCR\/ABL to STAT5 activation in myeloid leukemia cells","volume":"21","author":"Klejman","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0205","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1093\/emboj\/18.17.4754","article-title":"STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells","volume":"18","author":"Nosaka","year":"1999","journal-title":"EMBO J"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0210","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.191.6.977","article-title":"Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL","volume":"191","author":"Horita","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0215","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0220","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Critical role for Gab2 in transformation by BCR\/ABL","volume":"1","author":"Sattler","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0225","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","article-title":"Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway","volume":"16","author":"Skorski","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0230","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","article-title":"Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells","volume":"86","author":"Skorski","year":"1995","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0235","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1182\/blood-2003-07-2193","article-title":"Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells","volume":"103","author":"Kharas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-08-0801","article-title":"Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy","volume":"8","author":"Ihle","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0245","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1101\/gad.887201","article-title":"Regulation of translation initiation by FRAP\/mTOR","volume":"15","author":"Gingras","year":"2001","journal-title":"Genes Dev"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0250","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0255","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1002\/j.1460-2075.1995.tb00257.x","article-title":"Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E","volume":"14","author":"Haghighat","year":"1995","journal-title":"EMBO J"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0260","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0265","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.1038\/35010581","article-title":"An encore for ribosome biogenesis in the control of cell proliferation","volume":"2","author":"Thomas","year":"2000","journal-title":"Nat Cell Biol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0270","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/sj.emboj.7600193","article-title":"Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases","volume":"23","author":"Raught","year":"2004","journal-title":"EMBO J"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0275","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr Biol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0280","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1097-2765(02)00636-6","article-title":"Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control","volume":"10","author":"Loewith","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0285","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/emboj.2008.120","article-title":"The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C","volume":"27","author":"Facchinetti","year":"2008","journal-title":"EMBO J"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0290","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1073\/pnas.0400063101","article-title":"Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs","volume":"101","author":"Mohi","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0295","doi-asserted-by":"crossref","first-page":"12469","DOI":"10.1073\/pnas.1005114107","article-title":"Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells","volume":"107","author":"Carayol","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0300","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1126\/science.278.5338.687","article-title":"Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt","volume":"278","author":"del Peso","year":"1997","journal-title":"Science"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0305","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.onc.1208421","article-title":"Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells","volume":"24","author":"Essafi","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0310","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0315","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2004-02-0711","article-title":"Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha","volume":"104","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0320","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0325","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0330","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11899-010-0043-0","article-title":"Targeting chronic myeloid leukemia stem cells","volume":"5","author":"Helgason","year":"2010","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0335","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2004-12-4764","article-title":"Can we afford to let sleeping dogs lie?","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0340","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0345","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606","volume":"111","author":"Konig","year":"2008","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0350","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Jorgensen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0355","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0360","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0365","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V97.3.720","article-title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3","volume":"97","author":"Holyoake","year":"2001","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0370","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0375","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood-2009-01-202606","article-title":"The leukemic stem cell niche: current concepts and therapeutic opportunities","volume":"114","author":"Lane","year":"2009","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0380","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.drup.2009.06.001","article-title":"Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches","volume":"12","author":"Konopleva","year":"2009","journal-title":"Drug Resist Updat"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0385","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature04703","article-title":"Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells","volume":"441","author":"Yilmaz","year":"2006","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0390","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.stem.2010.09.015","article-title":"mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion","volume":"7","author":"Lee","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0395","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0400","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0405","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0410","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0415","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0420","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0425","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0430","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood-2002-05-1578","article-title":"Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells","volume":"100","author":"Luzzatto","year":"2002","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0435","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0440","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0445","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0450","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0455","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0460","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0465","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","article-title":"Drug transporters and imatinib treatment: implications for clinical practice","volume":"17","author":"Eechoute","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0470","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0475","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/excr.1999.4732","article-title":"Src family tyrosine kinases and growth factor signaling","volume":"254","author":"Abram","year":"2000","journal-title":"Exp Cell Res"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0485","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.leu.2402778","article-title":"The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains","volume":"17","author":"Stanglmaier","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0490","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia","volume":"36","author":"Hu","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0495","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0500","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells","volume":"111","author":"Wu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0505","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1073\/pnas.89.16.7491","article-title":"Wild-type p53 is a cell cycle checkpoint determinant following irradiation","volume":"89","author":"Kuerbitz","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0510","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1126\/science.1090072","article-title":"p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa","volume":"302","author":"Villunger","year":"2003","journal-title":"Science"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0515","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0520","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1073\/pnas.0602402103","article-title":"Loss of p53 impedes the antileukemic response to BCR-ABL inhibition","volume":"103","author":"Wendel","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0525","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/emboj\/17.2.384","article-title":"Bim: a novel member of the Bcl-2 family that promotes apoptosis","volume":"17","author":"O'Connor","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0530","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","article-title":"Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function","volume":"22","author":"Luciano","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0535","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1158\/0008-5472.CAN-05-0972","article-title":"Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR\/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds","volume":"65","author":"Aichberger","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0540","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0606176103","article-title":"Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic","volume":"103","author":"Kuroda","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0545","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/MCB.24.14.6172-6183.2004","article-title":"Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors","volume":"24","author":"Kuribara","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0550","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ejca.2009.04.005","article-title":"Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia","volume":"45","author":"San Jose-Eneriz","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0555","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1101\/gad.1599207","article-title":"Autophagy: process and function","volume":"21","author":"Mizushima","year":"2007","journal-title":"Genes Dev"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0560","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/45257","article-title":"Induction of autophagy and inhibition of tumorigenesis by beclin 1","volume":"402","author":"Liang","year":"1999","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0565","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nrd2272","article-title":"Potential therapeutic applications of autophagy","volume":"6","author":"Rubinsztein","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0570","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/j.1349-7006.2008.00932.x","article-title":"Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors","volume":"99","author":"Mishima","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0575","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0580","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.molcel.2009.02.015","article-title":"From promiscuity to precision: protein phosphatases get a makeover","volume":"33","author":"Virshup","year":"2009","journal-title":"Mol Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0585","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10555-008-9119-x","article-title":"Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias","volume":"27","author":"Perrotti","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0590","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000067425","article-title":"Role of serine\/threonine protein phosphatase in Alzheimer's disease","volume":"11","author":"Tian","year":"2002","journal-title":"Neurosignals"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0595","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0968-0004(03)00091-4","article-title":"The \u2018Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling","volume":"28","author":"Neel","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0600","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1128\/MCB.20.5.1526-1536.2000","article-title":"Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity","volume":"20","author":"Shi","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0605","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1097-2765(00)80287-7","article-title":"Opposing actions of CSW and RasGAP modulate the strength of Torso RTK signaling in the Drosophila terminal pathway","volume":"2","author":"Cleghon","year":"1998","journal-title":"Mol Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0610","doi-asserted-by":"crossref","first-page":"9498","DOI":"10.1074\/jbc.M110547200","article-title":"Regulation of the mitogen-activated protein kinase signaling pathway by SHP2","volume":"277","author":"Cunnick","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0615","doi-asserted-by":"crossref","first-page":"23102","DOI":"10.1074\/jbc.M110.212662","article-title":"Sprouty-related Ena\/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein (SPRED1), a tyrosine-protein phosphatase non-receptor type 11 (SHP2) substrate in the Ras\/extracellular signal-regulated kinase (ERK) pathway","volume":"286","author":"Quintanar-Audelo","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0620","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0625","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00043426-199911000-00014","article-title":"Juvenile myelomonocytic leukemia and Noonan syndrome","volume":"21","author":"Choong","year":"1999","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0630","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2004-10-4057","article-title":"Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia","volume":"106","author":"Xu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0635","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","article-title":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer","volume":"275","author":"Li","year":"1997","journal-title":"Science"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0640","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2009-06-228130","article-title":"PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice","volume":"115","author":"Peng","year":"2010","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0645","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1034\/j.1600-0609.2000.90181.x","article-title":"Mutational analysis of the tumour suppressor gene MMAC1\/PTEN in malignant myeloid disorders","volume":"65","author":"Aggerholm","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0650","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0898-6568(00)00123-6","article-title":"Protein phosphatase 2A: the Trojan Horse of cellular signaling","volume":"13","author":"Sontag","year":"2001","journal-title":"Cell Signal"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0655","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1128\/MCB.22.5.1352-1359.2002","article-title":"Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta","volume":"22","author":"Ivaska","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0660","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1093\/emboj\/20.15.4122","article-title":"Protein phosphatase 2A and its B56 regulatory subunit inhibit Wnt signaling in Xenopus","volume":"20","author":"Li","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0665","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0670","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cell.2007.04.044","article-title":"CIP2A inhibits PP2A in human malignancies","volume":"130","author":"Junttila","year":"2007","journal-title":"Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0675","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.1038\/sj.onc.1209038","article-title":"Involvement of PP2A in viral and cellular transformation","volume":"24","author":"Arroyo","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0680","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/sj.onc.1204279","article-title":"Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene","volume":"20","author":"Ruediger","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0685","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1182\/blood-2010-08-304477","article-title":"Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression","volume":"117","author":"Lucas","year":"2011","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0690","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1182\/blood-2010-08-300772","article-title":"Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A","volume":"117","author":"Salas","year":"2011","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0695","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0700","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4065\/81.7.973","article-title":"Chronic myeloid leukemia: diagnosis and treatment","volume":"81","author":"Quintas-Cardama","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0705","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0710","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0715","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0720","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells","volume":"103","author":"Chu","year":"2004","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0725","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/asheducation-2008.1.427","article-title":"Novel agents in CML therapy: tyrosine kinase inhibitors and beyond","volume":"2008","author":"Melo","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0730","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/sj.leu.2403949","article-title":"Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells","volume":"19","author":"Chuah","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0735","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood.V97.5.1404","article-title":"Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR\/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia","volume":"97","author":"Peters","year":"2001","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0740","first-page":"131","article-title":"Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro","volume":"61","author":"End","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0745","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2002-07-1973","article-title":"Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0750","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cncr.21590","article-title":"Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy","volume":"106","author":"Borthakur","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0755","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2007-09-112573","article-title":"BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors","volume":"111","author":"Copland","year":"2008","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0760","first-page":"5716","article-title":"Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin","volume":"63","author":"Ly","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0765","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.onc.1209901","article-title":"A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation","volume":"26","author":"Prabhu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0770","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0775","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrd3374","article-title":"Harnessing synthetic lethal interactions in anticancer drug discovery","volume":"10","author":"Chan","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0780","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","article-title":"Wnt\/Ca2+\/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl","volume":"18","author":"Gregory","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0785","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.beha.2009.07.006","article-title":"The blast phase of chronic myeloid leukaemia","volume":"22","author":"Silver","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0790","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0795","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0800","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0805","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0810","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1073\/pnas.0900189106","article-title":"Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation","volume":"106","author":"Abrahamsson","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0815","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1158\/0008-5472.CAN-08-1101","article-title":"BCR\/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair","volume":"68","author":"Cramer","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0820","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/03093640701859089","article-title":"BCR\/ABL, DNA damage and DNA repair: implications for new treatment concepts","volume":"49","author":"Skorski","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"Suppl. 1","key":"10.1016\/B978-0-12-396456-4.00007-9_bb0825","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10428194.2010.546912","article-title":"Chronic myeloid leukemia cells refractory\/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state","volume":"52","author":"Skorski","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0830","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0835","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/leu.2010.101","article-title":"BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase\/blast crisis CML patients","volume":"24","author":"Marega","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0840","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ccr.2004.10.015","article-title":"MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors","volume":"6","author":"Huntly","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0845","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.emboj.7601485","article-title":"Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation","volume":"26","author":"Coluccia","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0850","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood.V112.11.189.189","article-title":"Activation of PP2A by FTY720 inhibits survival and self-renewal of the Ph(+) chronic myelogenous leukemia (CML) CD34+\/CD38\u2212 stem cell through the simultaneous suppression of BCR\/ABL and BCR\/ABL\u2013independent signals","volume":"112","author":"Neviani","year":"2008","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0855","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1128\/MCB.24.15.6539-6549.2004","article-title":"Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development","volume":"24","author":"Ueda","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0860","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V118.21.963.963","article-title":"Targeting of a novel MNK\u2013eIF4E-\u03b2-catenin axis in blast crisis chronic myelogenous leukemia inhibits leukemia stem cell function","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0865","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-12-385071-3.00006-X","article-title":"Stem cells in normal development and cancer","volume":"95","author":"D'Angelo","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0870","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1158\/1078-0432.CCR-09-2846","article-title":"Targeting Hedgehog\u2014a cancer stem cell pathway","volume":"16","author":"Merchant","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0875","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0880","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0885","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1073\/pnas.0504337103","article-title":"Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling","volume":"103","author":"Riobo","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb9005","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.cell.2010.01.007","article-title":"miR\u2013328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts","volume":"140","author":"Eiring","year":"2010","journal-title":"Cell"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0890","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.2005.07.799","article-title":"Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions","volume":"23","author":"Pao","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0895","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0900","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nm.1973","article-title":"Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion","volume":"15","author":"Sato","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0905","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0910","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jcp.21908","article-title":"The hematopoietic stem cell niche: low in oxygen but a nice place to be","volume":"222","author":"Eliasson","year":"2010","journal-title":"J Cell Physiol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0915","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1158\/0008-5472.CAN-08-1959","article-title":"Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies","volume":"69","author":"Komarova","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0920","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.semcancer.2005.07.002","article-title":"Emergence and prevention of resistance against small molecule inhibitors","volume":"15","author":"Wodarz","year":"2005","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0925","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0930","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJMra1010600","article-title":"Genomics and drug response","volume":"364","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-12-396456-4.00007-9_bb0935","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJM199502023320508","article-title":"Human DNA polymorphism","volume":"332","author":"Housman","year":"1995","journal-title":"N Engl J Med"}],"container-title":["Progress in Molecular Biology and Translational Science","Protein Phosphorylation in Health and Disease"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T13:29:06Z","timestamp":1686749346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780123964564000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"ISBN":["9780123964564"],"references-count":188,"URL":"https:\/\/doi.org\/10.1016\/b978-0-12-396456-4.00007-9","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}